Estrogen-regulated feedback loop limits the efficacy of estrogen receptor–targeted breast cancer therapy

In Vivo Pharmacodynamic Imaging of Proteasome Inhibition

(2018) Erin A. Kimbrel et al.   Molecular Imaging

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

Synthetic lethality and cancer

(2017) Nigel J. O'Neil et al.   NATURE REVIEWS GENETICS

Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance

(2016) Richard Marcotte et al.   CELL

Targeted Combinations for Hormone Receptor–Positive Advanced Breast Cancer: Who Benefits?

(2016) Stephen R.D. Johnston   JOURNAL OF CLINICAL ONCOLOGY

Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting

(2016) A. J. Aguirre et al.   Cancer Discovery

Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary

(2016) Hope S. Rugo et al.   Journal of Oncology Practice

Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis

(2015) Sidi Chen et al.   CELL

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities

(2015) Traver Hart et al.   CELL

A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks

(2015) Oren Parnas et al.   CELL

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

(2015) Stephen R. D. Johnston   JNCI-Journal of the National Cancer Institute

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Endocrine resistance in breast cancer – An overview and update

(2015) Robert Clarke et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy

(2015) Ping Fan et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification and characterization of essential genes in the human genome

(2015) T. Wang et al.   SCIENCE

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

(2015) Stephen R. D. Johnston   JNCI-Journal of the National Cancer Institute

Differential Regulation of Estrogen Receptor   Expression in Breast Cancer Cells by Metastasis-Associated Protein 1

(2014) H.-J. Kang et al.   CANCER RESEARCH

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer

(2014) Luis J. Schwarz et al.   JOURNAL OF CLINICAL INVESTIGATION

High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells

(2014) Yuexin Zhou et al.   NATURE

Improved vectors and genome-wide libraries for CRISPR screening

(2014) Neville E Sanjana et al.   NATURE METHODS

PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells

(2013) Gilles Buchwalter et al.   CANCER CELL

Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance

(2013) A. K. Dunbier et al.   CLINICAL CANCER RESEARCH

The exact probability distribution of the rank product statistics for replicated experiments

(2013) Rob Eisinga et al.   FEBS LETTERS

Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer

(2013) Stefan Werner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library

(2013) Hiroko Koike-Yusa et al.   NATURE BIOTECHNOLOGY

A screen for morphological complexity identifies regulators of switch-like transitions between discrete cell shapes

(2013) Zheng Yin et al.   NATURE CELL BIOLOGY

Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase

(2013) Wei-Lan Yeh et al.   PLoS One

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

Genetic Screens in Human Cells Using the CRISPR-Cas9 System

(2013) Tim Wang et al.   SCIENCE

Regulation of the Src Family Kinases by Csk

(2012) Masato Okada   International Journal of Biological Sciences

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

(2012) Caryn S. Ross-Innes et al.   NATURE

Grhl2 Determines the Epithelial Phenotype of Breast Cancers and Promotes Tumor Progression

(2012) Xiaoyu Xiang et al.   PLoS One

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment

(2011) S C Drury et al.   ENDOCRINE-RELATED CANCER

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

(2011) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen

(2011) A. M. Mendes-Pereira et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression and Relevance of TRPS-1: A New GATA Transcription Factor in Breast Cancer

(2011) Jie Qing Chen et al.   Hormones & Cancer

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Growth factor stimulation induces a distinct ER  cistrome underlying breast cancer endocrine resistance

(2010) M. Lupien et al.   GENES & DEVELOPMENT

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

(2010) Todd W. Miller et al.   JOURNAL OF CLINICAL INVESTIGATION

Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer

(2010) W. Fraser Symmans et al.   JOURNAL OF CLINICAL ONCOLOGY

Nucleosome dynamics define transcriptional enhancers

(2010) Housheng Hansen He et al.   NATURE GENETICS

The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function

(2010) David Warde-Farley et al.   NUCLEIC ACIDS RESEARCH

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

(2010) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Formation of endothelial lumens requires a coordinated PKC -, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation

(2009) W. Koh et al.   JOURNAL OF CELL SCIENCE

The endocrine prevention of breast cancer

(2008) Anthony Howell   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

(2008) Sherene Loi et al.   BMC GENOMICS

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

(2008) Yi Zhang et al.   BREAST CANCER RESEARCH AND TREATMENT

FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription

(2008) Mathieu Lupien et al.   CELL